CDA and breast cancer: In addition, A3A often provides the majority of cytidine deaminase activity and APOBEC-signature mutations in breast cancer cell lines (even in the presence of A3B and A3H-I) in part due to its stronger cytidine deaminase activity and unique resistance to RNA inhibition17,22.